FibroBiologics Reports Q2 2026 Results, Advances Wound Care Trial
FibroBiologics announced its financial results for the second quarter of 2026. The company is also progressing in a clinical trial evaluating its CYWC628 wound care candidate for diabetic foot ulcers.
FibroBiologics has reported its financial results for the second quarter of 2026, alongside progress in its clinical development.
The company has initiated patient dosing in a Phase 1/2 clinical trial assessing the CYWC628 candidate for the treatment of diabetic foot ulcers. FibroBiologics anticipates reporting interim results from this trial in the second half of 2026.
This advancement marks a significant step in the development of new therapeutic options for diabetic foot ulcers, a serious health condition that can lead to severe complications and amputations.
While specific financial figures were not detailed, the company reiterated its focus on advancing its clinical development pipeline.